Federal Register / Vol. 82, No. 175 / Tuesday, September 12, 2017 / Notices 42823 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average burden 

per response 

(in hours) 

Total burden 

hours 

(rounded up) 

Missing Report Form ......................................................... 29 1 29 .08 3 

Subject Statement and Dispute ......................................... 3,547 1 3,547 .75 2,661 

Request for Dispute Resolution ......................................... 99 1 99 8 792 

Electronic Transfer of Funds (EFT) Authorization ............. 654 1 654 .08 53 

Authorized Agent Designation ........................................... 213 1 213 .25 54 

Account Discrepancy ......................................................... 10 1 10 .25 3 

New Administrator Request ............................................... 3,016 1 3,016 .08 242 

Query Credit Purchase ...................................................... 789 1 789 .08 64 

Educational Request .......................................................... 10 1 10 .08 1 

Account Balance Transfer ................................................. 10 1 10 .08 1 

Total ............................................................................ 6,059,761 ........................ 6,059,761 .......................... 326,120 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Amy McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–19252 Filed 9–11–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Developmental Biology 

Subcommittee. 

Date: October 2, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda Downtown, 

7335 Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Cathy J. Wedeen, Ph.D., 

Scientific Review Officer, Division of 

Scientific Review, OD, Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development, NIH, DHHS, 6710 

B Rockledge Drive, Bethesda, Maryland 

20892, 301–435–6878, wedeenc@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 6, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–19232 Filed 9–11–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: Government owned 

intellectual property covering imaging 

agents with improved renal clearance 

available for licensing and 

commercialization. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive, 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: The 

inventions listed below are owned by an 

agency of the U.S. Government and are 

available for licensing in the U.S. in 

accordance with 35 U.S.C. 209 and 37 

CFR part 404 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. A description of the 

technology available for licensing 

follows. 

Evans Blue Dye Derivatives for Serum 

Albumin Labeling 

Description of Technology: The 

invention is an imaging agent and 

method of its use for imaging blood 

pools and the lymphatic system. The 

imaging agent binds with high affinity 

to serum albumin, the most abundant 

serum protein, and can be tagged with 

several isotopes making it suitable for 

magnetic resonance imaging or positron 

emission tomographic imaging. To date, 

only very few blood-pool tracers have 

been introduced for positron emission 

tomography. The existing ones have 

short half-lives (20.4 min for 11C and 

2.05 min for 15O) and thus can only be 

used in centers with an in-house 

cyclotron. Compared with these 

radiometals, 18F has the advantages of 

being a pure position emitter with ideal 

half-life. It is the dominant radioisotope 

used for PET imaging for both clinical 

applications and preclinical 

investigations. Evans blue dye has been 

an important tool in many physiological 

and clinical investigations because of its 


pmangrum on DSK3GDR082PROD with NOTICES1